Real-world effectiveness of palbociclib in combination with an aromatase inhibitor in HR+/HER2- bone-only metastatic breast cancer - PubMed
3 hours ago
- #metastatic breast cancer
- #CDK4/6 inhibitors
- #real-world evidence
- Study compares effectiveness of palbociclib (PAL) plus aromatase inhibitor (AI) vs. AI alone in HR+/HER2- bone-only metastatic breast cancer (MBC).
- Retrospective analysis using Flatiron Health Research database included 974 patients (538 PAL + AI, 436 AI alone).
- PAL + AI showed significantly longer overall survival (63.4 vs. 51.3 months), real-world progression-free survival (23.0 vs. 18.2 months), and time to chemotherapy (47.9 vs. 40.6 months).
- Results remained consistent in sensitivity analyses, supporting PAL + AI as a superior first-line treatment for bone-only MBC.
- Study highlights real-world benefits of CDK4/6 inhibitors in a specific MBC subgroup with limited prior data.